Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) and Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.
Volatility & Risk
Cardiol Therapeutics has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 2.49, indicating that its share price is 149% more volatile than the S&P 500.
Profitability
This table compares Cardiol Therapeutics and Black Diamond Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cardiol Therapeutics | N/A | -194.40% | -129.07% |
| Black Diamond Therapeutics | N/A | -68.08% | -49.65% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cardiol Therapeutics | 0 | 0 | 4 | 1 | 3.20 |
| Black Diamond Therapeutics | 0 | 0 | 4 | 0 | 3.00 |
Cardiol Therapeutics presently has a consensus target price of $8.75, suggesting a potential upside of 600.00%. Black Diamond Therapeutics has a consensus target price of $15.50, suggesting a potential upside of 588.89%. Given Cardiol Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Cardiol Therapeutics is more favorable than Black Diamond Therapeutics.
Insider and Institutional Ownership
12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by company insiders. Comparatively, 8.9% of Black Diamond Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Cardiol Therapeutics and Black Diamond Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cardiol Therapeutics | $60,000.00 | 1,702.15 | -$20.84 million | ($0.39) | -3.21 |
| Black Diamond Therapeutics | N/A | N/A | -$82.44 million | ($1.33) | -1.69 |
Cardiol Therapeutics has higher revenue and earnings than Black Diamond Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.
About Cardiol Therapeutics
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
About Black Diamond Therapeutics
Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
